drugset / Trial / NCT01340625
Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions
RandomizedCrossoverOpen-label
Summary
This study compared the relative bioavailability (rate and extent of absorption) of 0.4 mg/35 mcg Norethindrone and Ethinyl Estradiol Chewable Tablets by Teva Pharmaceuticals, USA with that of 0.4 mg/35 mcg Ovcon® 35 Fe Chewable Tablets manufactured by Warner Chilcott Company, Inc., following a single oral dose (2 \* 0.4 mg/35 mcg chewable tablets) in healthy female adult volunteers administered under fasting conditions.
Timeline
- Start
- 2006-12
- Primary completion
- 2007-01
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Norethindrone/Ethinyl Estradiol | Unknown | 35 ug | Oral |
| Subject | Norethindrone/Ethinyl Estradiol | Unknown | 0.4 mg | Oral |
Indications
No indication recorded.